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Key questions
What is already known about this subject?
 ► While a comprehensive systematic review and me-
ta-analysis had shown that the use of natriuretic 
peptide (NP) can reduce the risk of hospitalisation, 
specific guidance on which form of intervention 
could be adopted in practice was missing.
What does this study add?
 ► Our analysis highlights which components of NP-
guided monitoring of heart failure may be essential 
in reducing heart failure hospitalisation.
How might this impact on clinical practice?
 ► Our analyses have helped reveal which components 
of monitoring are perhaps unnecessary and which 
components may be essential in reducing admis-
sions for patients with heart failure.
AbstrAct
Aim To identify the key components of natriuretic peptide 
(NP)-guided treatment interventions which reduced 
hospitalisation in patients with heart failure (HF).
Methods and results We extracted detailed information 
on the components of interventions from studies of NP-
guided treatment of HF identified in a previous systematic 
review. We used meta-regression techniques to assess 
univariate associations between components and the 
strength of the reduction in HF hospitalisations and all-
cause mortality. A Bayesian meta-analysis approach was 
used to re-estimate study-level effects in order to identify 
the study with the most effective NP-guided monitoring 
intervention. Finally, we examined the intervention options 
common to the studies in which the 95% credible interval 
excluded no effect. We identified eight components of NP-
guided treatment from ten studies. Univariate comparisons 
produced mainly equivocal results, but single trial 
choice and common components analysis led to similar 
conclusions. Using a predefined treatment protocol, setting 
a stringent NP target (N-terminal pro-B-type natriuretic 
peptide of 1000 pg/mL or B-type natriuretic peptide 100 
pg/mL) and including a relative targetwere potential key 
components to reducing HF hospitalisations using NP-
guided therapy.
Conclusion This analysis provides a description of the 
key components of NP-guided treatment which could 
help policy makers develop specific recommendations for 
HF management. Our research suggests that NP-guided 
interventions could be simplified, but more research in 
relevant health settings, such as primary care, is required.
IntroduCtIon
B-type natriuretic peptide (BNP) and the 
biologically inactive N-terminal fragment 
(NT-proBNP) are cardiac hormones collec-
tively known as natriuretic peptides (NPs) 
that are synthesised and secreted in the 
ventricular myocardium.1 Serum concen-
trations are related to left ventricular filling 
pressures, and can be useful to discriminate 
between heart failure (HF) and other causes 
of breathlessness.2 Concentrations are higher 
in untreated or decompensated HF and fall 
after treatment.3 Therefore, NPs are a useful 
marker of cardiac function and treatment 
response.
Monitoring NP concentrations may guide 
decisions about when to alter the dose of 
medication,4 but evidence on the benefit 
of guiding therapy using plasma concentra-
tions of NP has been conflicting.3 5 The most 
recent systematic review of 18 randomised 
controlled trials of NP-guided treatment of 
HF reported no evidence on reduction in 
all-cause mortality nor HF mortality,6 but 
did find evidence that NP-guided treatment 
reduced the number of hospital admissions. 
As with many systematic reviews, these studies 
implemented closely related but not identical 
versions of NP-guided treatment. Therefore, 
it is not clear which version should be imple-
mented in clinical practice, where in the 
patient pathway the test should be conducted 
or which features of the intervention are crit-
ical for effectiveness. Current methods to 
guide the transition from research evidence 
to clinical practice are poorly developed, and 
clinical guidance is often not covered in the 
systematic review literature.7 One method-
ological approach to overcome the challenges 
of moving from evidence to practice is to use 
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1. Setting Where the majority of the 
patients’ management took 
place, that is, specialist 
outpatient or at ambulatory 
clinics.






Was telephone contact 
with a healthcare 











Did the studies use 
predefined rules/




5. Targets Was the target NP level 
based on an absolute level 
or were relative changes to 
baseline considered?
1. Absolute.
2. Incorporated relative 
changes.




7. Trigger Was a relative value set 






What was the most 
frequent rate of monitoring 
(either in titration or control 
phase)?
1. More frequent than 
every 3 months.
2. Every 3 months or 
longer
*Threshold for less/more stringent was 100 pg/ml (or equivalent 
units) for BNP and 1000 pg/ml for NT-proBNP.
NP, natriuretic peptide.
an intervention synthesis as described by Glasziou et al.8 
This consists of three broad approaches: (1) choosing a 
single trial based on criteria such as feasibility, cost and 
effectiveness; (2) common components hybrid which 
extracts and recombines components based on frequency 
and importance; and (3) model-guided synthesis, an 
approach which models the mechanisms of action to 
assess the importance of the intervention components. 
The single trial-based choice and common components 
hybrid method is viable for a wide range of systematic 
reviews, whereas the model-guided synthesis is probably 
only possible for large systematic reviews.8
The aim of this study was to determine the effective 
intervention components which were associated with a 
reduction in hospitalisations for patients with HF. This 
could enable policy makers and practitioners to deter-
mine specific recommendations for monitoring HF.
Methods
Our intervention synthesis builds on a systematic review 
of the effectiveness of NP-guided monitoring for HF.6 In 
brief, the systematic review included trials comparing 
management guided by serial BNP or NT-proBNP with 
usual care. The primary outcome in the original review 
was all-cause mortality with secondary outcomes of HF 
mortality, HF admissions, adverse events, costs and 
quality of life. For our intervention synthesis, we used 
HF hospitalisations as the primary outcome and all-cause 
mortality as a secondary outcome. All-cause mortality was 
considered as a secondary outcome because in the orig-
inal systematic review NP-guided therapy was not associ-
ated with a significant reduction in all-cause mortality, 
whereas it was associated with a significant reduction in 
HF hospitalisations.
We contacted authors to obtain information regarding 
the interventions evaluated as part of the systematic 
review.6 For the purpose of the intervention synthesis, 
we went back to the original trial publications and 
attempted to gather as much detail on the components 
of intervention as possible. Two members of the team 
(AC and CB) extracted and coded the component 
information.
First, we examined univariate associations between 
each component and size of the relative risk (RR) reduc-
tion by comparing effect estimates in subcategories of 
each component. We compared the RRs of hospitalisa-
tion and all-cause mortality across component subgroups, 
using meta-regression to test for equality.9 We presented 
the estimated ratio of RRs with 95% CIs for each compo-
nent in a figure. For defining stringency of the target, 
we used the lowest threshold reported in the included 
studies and defined stringency as 100 pg/mL (or equiv-
alent units) for BNP and 1000 pg/mL for NT-proBNP. 
We converted targets in units of pmol/L for NT-proBNP 
using an online calculator10 and assumed that ng/L 
and pg/mL were equivalent (ie, 100 ng/L is the same 
as 100 pg/mL). We report thresholds in units of pg/mL 
because the majority of the studies in the review reported 
NP in this unit. Studies with higher targets were classed 
as not stringent. We looked at the frequency of moni-
toring across the whole length of the study (ie, titration 
and control phase). Studies were deemed to be ‘more 
frequent’ monitoring if at any time scheduled visits were 
at intervals less than every 3 months.
We then re-estimated the study-level RRs with 95% cred-
ible intervals using a Bayesian meta-analysis approach 
(see online supplementary file 1). This was to account for 
biases in which smaller studies report larger effect sizes.11
We first identified the trial with the largest RR reduction 
(single-trial choice) following re-estimation and assessed 
this version of the intervention. We then separated the 
trials into studies that appeared to have the ‘more effec-
tive’ versions of the intervention using the criteria of 
the 95% credible interval. The ‘more effective’ studies 
had a 95% credible interval which excluded ‘no differ-
ence’ (RR=1), whereas in the ‘less effective’ studies the 
95% credible interval crossed the line of ‘no difference’. 
Component options were selected for the new composite 
intervention based on which of the component choices 
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Figure 1 Results of the meta-regression of individual components.
Figure 2 Forest plot showing ‘shrinkage estimates’ of the 
relative risk (RR) of hospitalisation. NP, natriuretic peptide.
were more common to the ‘more effective’ studies with 
any ties considered equivocal.
results
The review found 3394 references and identified 18 
studies suitable for consideration. One further study has 
been published since the review was finished.12 HF hospi-
talisation rates were reported in 11 studies: Troughton et 
al,3 Jourdain et al,13 Anguita et al,14 Berger et al,15 Krupicka 
et al,16 Lainchbury et al,17 Karlström et al,18 Januzzi et al,19 
Schou et al,20 Skvortsov 201521 and Felker et al.12 Mortality 
outcomes were reported in six additional studies: Pfist-
erer et al,22 Beck-da-Silva et al,23 Persson et al,24 Eurlings 
et al,25 Shah et al26 and Shochat et al.27 Hospitalisation 
outcomes but not mortality were reported in Januzzi et 
al,19 and hence 16 studies were included in the secondary 
analysis. A flow chart showing the selection process can 
be found in online supplementary file 1.
We identified eight components of NP-guided treat-
ment from the original ten studies (table 1).
An evidence summary table that shows detailed descrip-
tions of the specific components used for each study can 
be found in online supplementary table S1.
Components and univariate associations with hospitalisation 
and all-cause mortality outcomes
Component 1: setting
Twelve of the studies were based in specialist HF or 
cardiology clinics. In four studies, the descriptions were 
ambiguous or unclear, and so were classed as non-speci-
fied or other.
Component 2: telephone contact
Only three studies in total included telephone contact as 
part of the intervention. In the Berger et al15 study, both 
the multidisciplinary care and NT-proBNP-guided inten-
sive management arms included telephone contact with 
an HF nurse. Similarly, the patients enrolled in the Schou 
et al20 study had free daily access to telephone consulta-
tions with an HF nurse who was supervised by cardiolo-
gists.
Component 3: education
Six studies included some form of an educational compo-
nent to their intervention. In some studies, education was 
aimed at promoting adherence to medication, whereas 
in others education was broader and promoted enhance-
ment of self-management and lifestyle.
Component 4: treatment protocols
Eight studies used predefined (but different) treat-
ment protocols which laid out specific instructions for 
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Table 2 HF hospitalisation: Presence or absence of component options split by studies with study-specific credible intervals 
excluding the null effect (RR=1) (lower part of the table) and studies with credible intervals not excluding the null effect (upper 
part of the table)























Studies not excluding, RR=1
  Anguita et al14 ✔ ✗ ✗ ✗ ✗ ✔ ✗ ✔
  Felker et al12 ✔ ✗ ✗ ✗ ✗ ✔ ✗ ✔
  Karlström et al18 ✔ ✗ ✔ ✔ ✗ ✗ ✗ ✔
  Lainchbury et al17 ✗ ✗ ✔ ✗ ✗ ✗ ✗ ✗
  Schou et al20 ✔ ✔ ✔ ✔ NA NA ✔ ✔
✔ Proportion 0.80 0.20 0.6 0.40 0 0.5 0.20 0.80
Studies excluding, RR=1
  Berger et al15 ✔ ✔ ✔ ✔ ✗ ✗ ✔ ✔
  Januzzi et al19 ✔ ✗ ✗ ✗ ✗ ✔ ✗ ✗
  Jourdain et al13 ✗ ✗ ✗ ✗ ✗ ✔ ✗ ✗
  Krupicka et al16 ✔ ✗ ✗ ? ✔ ✔ ✗ ✗
  Skvortsov et al21 
2015
✔ ✗ ✗ ✔ ✔ ✔ ✗ ✔
  Troughton et al3 ✔ ✗ ✗ ✔ ✗ ✗ ✗ ✔




✔ ✗ ✗ ✔ ✔ ✔ ✗ –
Component options for new composite intervention are selected based on the most common option in the ‘more effective’ studies.
NA, not available;NP, natriuretic peptide;RR, relative risk.
uptitration of therapy. Six studies used investigator 
judgement to modify therapy in response to NP moni-
toring. The Januzzi et al 19 study justified this choice by 
stating that ‘it was believed that such an approach would 
confound the concept of standard HF, which does not 
typically rely on such care’. In two of the studies, it was 
not possible to ascertain if a predefined or investigator 
judgement approach was used.
Component 5: NP targets
Nine studies set goals based on absolute target NP levels, 
although these varied in stringency. Six studies included 
a relative NP target based on baseline NP level. For 
example, Skvortsov et al21 set a goal of getting NT-proBNP 
below 1000 pg/mL or 50% lower than the baseline 
NT-proBNP level. Schou et al20 did not set a target.
Component 6: target stringency
In all but one study, a single target was set. Karlström 
et al18 defined BNP targets of 150 ng/L in patients <75 
years and 300 ng/L (BNP) target for patients over 75. 
Five studies set ‘stringent’ targets and ten studies set ‘less 
stringent’ targets. As Schou et al20 did not set a target, we 
did not include this study in this comparison.
Component 7: NP trigger
None of the studies made no mention of using a specific 
trigger value of NP and set only an overall target level 
NP. Seven studies were classed as having set ‘Relative’ 
triggers to change therapy. For example, the Berger et 
al15 study used an increase or decrease of 30% to opti-
mise therapy. Similarly the Schou et al20 study set a refer-
ence change value of 30% increase from baseline to take 
action and mandated completion of a clinical checklist in 
the absence of symptoms or signs of congestion.
Component 8: monitoring frequency
Twelve studies monitored NP more frequently than every 
3 months and four studies (Anguita et al,14 Jourdain et 
al,13 Krupicka et al,16 and Lainchbury et al17) set moni-
toring intervals at 3 months or longer (figure 1).
single-trial-based choice
The Skvortsov et al21 study had the largest RR reduction in 
hospital admissions and all-cause mortality using standard 
meta-analysis methods (see online supplementary file 1), 
but this was a fairly small study (N=76) and the effect 
may be optimistic (a small study effect). The Bayesian 
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Table 3 All-cause mortality: presence or absence of component options split by studies with study-specific credible intervals 
excluding the null effect (RR=1) (lower part of the table) and studies with credible intervals not excluding the null effect (upper 

























Studies not excluding, RR=1
  Anguita et al14 ✔ ✗ ✗ ✗ ✗ ✔ ✗ ✔
  Beck-da-Silva et al23 ✔ ✗ ✗ ✔ ✔ ✗ ✔ ✔
  Berger et al15 ✔ ✔ ✔ ✔ ✗ ✗ ✔ ✔
  Karlström et al18 ✔ ✗ ✔ ✔ ✗ ✗ ✗ ✔
  Krupicka et al16 ✔ ✗ ✗ ? ✔ ✔ ✗ ✗
  Lainchbury et al17 ✗ ✗ ✔ ✗ ✗ ✗ ✗ ✗
  Persson et al24 ✗ ✗ ✗ ✗ ✔ ✗ ✔ ✔
  Schou et al20 ✔ ✔ ✔ ✔ NA NA ✔ ✔
  Shah et al26 ✔ ✔ ✔ ✗ ✗ ✗ ✔ ✔
✔ Proportion 0.778 0.333 0.555 0.5 0.375 0.25 0.555 0.778
Studies excluding, RR=1
  Eurlings et al25 ✔ ✗ ✔ ✔ ✔ ✗ ✔ ✔
  Felker et al12 ✔ ✗ ✗ ✗ ✗ ✔ ✗ ✔
  Jourdain et al13 ✗ ✗ ✗ ✗ ✗ ✔ ✗ ✗
  Pfisterer et al22 ✔ ✗ ✗ ✔ ✗ ✗ ✗ ✔
  Shochat et al27 ✗ ✗ ✗ ? ✔ ✗ ✔ ✔
  Skvortsov et al21 ✔ ✗ ✗ ✔ ✔ ✔ ✗ ✔
  Troughton et al3 ✔ ✗ ✗ ✔ ✗ ✗ ✗ ✔
✔ Proportion 0.714 0 0.142 0.667 0.429 0.429 0.286 0.857
Proposed new composite 
intervention
✗ ✗ ✗ ✔ ✔ ✔ ✗ ✔
Component options for the new composite intervention are selected based on the most common option in the ‘more effective’ studies.
NA, not available;NP, natriuretic peptide;RR, relative risk.
‘shrinkage’ analysis, which re-estimates study-level effects, 
pulled back the Skvortsov et al21 study from an observed 
RR (95% CI) of 0.25 (0.09 to 0.67) to 0.54 (0.26 to 0.85) 
for hospitalisation and from 0.35 (0.12 to 0.98) to 0.78 
(0.58 to 0.96) for all-cause mortality. Following re-estima-
tion, the Skvortsov et al21 study remained the study with 
the largest reduction in both hospital admissions and 
all-cause mortality, but shrinkage analysis had the effect 
of making it comparable with Januzzi et al,19 Jourdain et 
al13 and Berger et al15 (figure 2).
Patients in the Skvortsov et al21 study were managed in 
a specialist HF clinic. The intervention did not include 
telephone contact or any specialist education compo-
nent. At each visit, NP measurement was considered in 
conjunction with clinical assessment, and specific instruc-
tions were given on the basis of clinical symptoms and 
NP trends. Target NP levels were stringent (NT-proBNP 
1000 pg/mL), but relative changes from baseline (>50% 
reduction) were also included. Outpatient monitoring 
was monthly in controlled patients and every 2 weeks in 
those whose clinical condition appeared to be deterio-
rating. A notable feature of the Skvortsov et al21 study is 
that, unlike the other studies, the majority of the patients 
recruited into the study were New York Heart Association 
(NYHA) stage 4 (see online supplementary file 1).
Common components approach
After re-estimation using the Bayesian approach, in the 
hospitalisation outcome, six studies had credible inter-
vals excluding RR of 1 (the ‘more effective’ interven-
tions) and five studies had credible intervals that crossed 
RR of 1 (considered ‘less-effective’ versions of the inter-
ventions). For all-cause mortality, seven studies had cred-
ible intervals that excluded 1 and the remaining nine had 
credible intervals that crossed 1. No component options 
were exclusive to the more effective studies (ie, occurred 
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in all of the more effective studies and in none of the 
less effective studies). Applying the common components 
approach to the hospitalisation outcome (table 2), our 
proposed new composite intervention would be based 
in a specialist clinic, would not include an education 
component or provide telephone contact but would use 
a predefined treatment protocol, aim to reduce NP to a 
stringent target (<1000 pg/mL), and also consider rela-
tive targets (eg, 50% reduction from baseline) but not 
include a relative trigger (ie, increasing doses based on 
short-term changes in NP). Applying the same method to 
the all-cause mortality outcomes (table 3), our composite 
intervention would be comprised of a pre-defined treat-
ment protocol, a relative and stringent target with more 
frequent monitoring. Monitoring frequency was consid-
ered equivocal for the hospitalisation outcome.
Component options based on all-cause mortality 
were the same as for the hospitalisation outcome, with 
the exception of monitoring frequency. For all-cause 
mortality, the studies that monitored more frequently 
than every 3 months outnumbered the studies moni-
toring less frequently. Only the Skvortsov et al21 study 
included all of these specific component options.
dIsCussIon
In our study we have attempted to identify the key compo-
nents of NP-guided monitoring for patients with chronic 
HF using an intervention synthesis approach. While a 
comprehensive systematic review and meta-analysis had 
shown that the use of NP can reduce the risk of hospital-
isation, specific guidance on which form of the interven-
tion could be adopted in practice was missing. Our anal-
yses have helped reveal which components are perhaps 
unnecessary and which components may be essential in 
reducing admissions for patients with HF.
The Bayesian meta-analytic approach had the effect 
of reducing heterogeneity in the all-cause mortality 
outcome, suggesting that most of the observed variation 
is attributable to sampling variability as opposed to ‘real’ 
treatment effect modification. For HF hospitalisation, 
the heterogeneity was preserved after the Bayes anal-
ysis, suggesting the observed differences in intervention 
efficacy may be real. While univariate analyses of indi-
vidual components produced mainly equivocal results, 
the single trial-based choice and common components 
analysis led to a similar conclusions; using a predefined 
treatment protocol and setting a stringent target along-
side a relative target are potentially key components in 
NP-guided therapy reducing HF hospitalisations.
Current guidelines from the European Society of Cardi-
ology (ESC)28 highlight the residual uncertainty about 
the value of NP-guided therapy and make no specific 
recommendations for monitoring. The National Insti-
tute for Health and Care Excellence suggests considering 
specialist monitoring of patients in whom uptitration is 
problematic or who have been admitted to the hospital.29 
A recent individual patient data meta-analysis reported 
that the benefit of NP-guided therapy is confined to 
patients with heart failure with reduced ejection frac-
tion (HFrEF), and although comorbidities were associ-
ated with mortality outcomes this was not the case for 
HF-related hospitalisations.30 Similarly, a meta-regression 
found limited evidence of effect modification around 
therapy types, NYHA class, and having hypertension or 
diabetes, but length of follow-up and age were associated 
with HF-related hospitalisations.31
Cocco et al32 also did examine why only some of the 
many NP-guided trials demonstrated encouraging trends. 
They concluded that the different approaches used in the 
studies with particular respect to patient selection (acute 
vs chronic forms of HF) and the choice of NP target were 
important. Some of the studies examined, set targets that 
were too high to reduce cardiac events, which is consis-
tent with our finding that stringency of target may be 
associated with reducing hospitalisation. Finally, they 
observed that target NP values were chosen empirically, as 
opposed to being evidence-based, and these levels varied 
significantly. As per the ESC position they also concluded 
that NP-guided therapy usually led to intensification of 
therapy,32 and this could potentially explain reductions 
in HF-related hospitalisations. We could not rule this out 
with the data available to us.
The results of this analysis can be generalised to a 
diverse patient group; all of the studies included people 
of older age (up to 85 years of age), while some but not 
all of the studies recruited patients with heart failure 
with preserved ejection fraction (HFpEF) as well as 
HFrEF. There were also patients represented from a 
wide spectrum of chronic HF, including asymptomatic 
and symptomatic forms of the disease, but not those 
with significant comorbidities, awaiting heart surgery 
or low life expectancy, who were excluded. Finally, the 
interventions were for the most part well described, 
and as part of the initial systematic review detailed 
information on the interventions used in the trials was 
obtained.
There are a number of limitations to our analysis. The 
initial systematic review only identified 10 studies that 
reported HF hospitalisation rates and 15 with all-cause 
mortality outcomes. Even with the addition of the most 
recent trial,12 this may be too few to be able to identify 
all of the ‘active’ components of most interventions. The 
small sample size is likely to have limited our ‘statistical 
power’ to detect all but the largest treatment covariate 
interactions. The studies that have evaluated the use of 
NP-guided monitoring in patients with HF are heteroge-
neous for factors other than the intervention components 
examined in this study. Therefore, a more nuanced anal-
ysis that is able to adjust for the varying demographic and 
clinical characteristic of the participants, outcome evalu-
ation and assay techniques may be required to determine 
the optimal approach to NP-guided monitoring. This is 
probably only possible with a comprehensive individual 
patient data meta-analysis including all of the relevant 
studies.
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By doing multiple comparisons in the univariate anal-
yses, we run the risk that a statistical difference could 
occur by chance. In fact, only 1 of the 16 comparisons 
we made was statistically significant at the 5% level, and 
it therefore seems more likely that with this number of 
studies we are more likely to be at risk of making a type 
2 error and missing real differences. In addition, the 
outcome does not take account of how long these hospital 
stays were and this could also have been important. In 
all of the studies contributing hospitalisation data, NP 
was managed in ambulatory clinics by HF specialists, and 
therefore does not provide any evidence that NP-guided 
monitoring if implemented in a primary care setting 
could reduce hospitalisation to the same degree. Berger et 
al15 warned that ‘deployment of their intervention using 
ambulatory HF specialists and home nurses may not be 
feasible in all health care systems, and further adaptation 
of this approach will be necessary in different settings’. 
Our analysis did not extend to considering monitoring 
with BNP versus NT-proBNP because in the initial review 
a stratified analysis comparing NT-proBNP with BNP with 
respect to all-cause and HF mortality, all-cause and HF 
admissions and quality of life showed no differences.6 
However, there is evidence to suggest that BNP immu-
noassays exhibit greater between-method variability 
than NT-proBNP assays (coefficient of variation (CV) 
for BNP=43.0%, CV for NT-proBNP=8.7%), suggesting 
that BNP immunoassays are affected by large systematic 
differences in analytical performance.33 On this evidence 
alone, one would favour NT-proBNP if NP-guided moni-
toring included setting a stringent target.
Lastly, adverse events were reported in only a few 
studies, and we have not been able to assess whether 
any specific version of the intervention is associated with 
more or fewer problems.
In this analysis we have attempted to provide informa-
tion about the critical features of NP-guided monitoring 
of chronic HF to reduce hospitalisation. While there 
are tools to aid the evaluation of complex interventions 
in trials,34 when it comes to meta-analysis we are reduc-
tionist and tend to focus on simple questions which 
may not translate to clinical practice. The approach 
used in this paper takes account of the complexity of 
NP-guided management (or therapy) as an interven-
tion and attempts to provide practical recommendations 
for monitoring. While the findings of this review were 
unable to unequivocally determine an optimal interven-
tion, a future intervention synthesis incorporating more 
data may provide clear procedural details of the essential 
elements of NP-guided monitoring. Further research to 
evaluate the clinical and cost-effectiveness of any imple-
mented NP-guided HF monitoring within different 
healthcare systems is also needed.
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